Imunon (IMNN) FCF Margin (2017 - 2022)
Imunon's (IMNN) quarterly FCF Margin came in at 4041.97% in Q4 2022, up 4901.0% YoY from 80.82% in Q4 2021, and down 7.57% on a QoQ basis from 3757.68% in Q3 2022.
Imunon (IMNN) FCF Margin (2017 - 2022) Analysis & Trends
Imunon (IMNN) has 6 years of FCF Margin data on file, last reported at 4041.97% in Q4 2022.
- Quarterly FCF Margin rose 4901.0% year-over-year to 4041.97% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 4672.94% (down 136590.0% YoY) and the FY2022 annual result came in at 4672.94%, down 136590.0% from the prior year.
- FCF Margin retreated to 4041.97% in Q4 2022, from 3757.68% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 4823.73% in Q4 2018 to a low of 6425.93% in Q1 2022.
- A 5-year average of 3333.04% and a median of 3752.81% in 2018 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2018 — FCF Margin soared 820485 bps — and 2019, when it tumbled 932720 bps.
- Tracing IMNN's FCF Margin over 5 years: stood at 4823.73% in 2018, then slumped by 193 bps to 4503.47% in 2019, then soared by 34 bps to 2989.44% in 2020, then tumbled by 37 bps to 4090.99% in 2021, then advanced by 1 bps to 4041.97% in 2022.
- The last three FCF Margin figures came in at 4041.97% (Q4 2022), 3757.68% (Q3 2022), and 4466.17% (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -4,041.97% |
| Sep 30, 2022 | -3,757.68% |
| Jun 30, 2022 | -4,466.17% |
| Mar 31, 2022 | -6,425.93% |
| Dec 31, 2021 | -4,090.99% |
| Sep 30, 2021 | -3,076.07% |
| Jun 30, 2021 | -2,170.35% |
| Mar 31, 2021 | -3,890.77% |
| Dec 31, 2020 | -2,989.44% |
| Sep 30, 2020 | -3,172.69% |
| Jun 30, 2020 | -2,361.45% |
| Mar 31, 2020 | -3,986.64% |
| Dec 31, 2019 | -4,503.47% |
| Sep 30, 2019 | -3,643.37% |
| Jun 30, 2019 | -3,794.86% |
| Mar 31, 2019 | -4,544.82% |
| Dec 31, 2018 | 4,823.73% |
| Sep 30, 2018 | -3,415.98% |
| Jun 30, 2018 | -3,403.87% |
| Mar 31, 2018 | -3,747.95% |